(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.53%) $79.42
(1.14%) $1.954
(0.70%) $2 327.10
(0.27%) $26.82
(1.29%) $967.20
(0.01%) $0.933
(-0.06%) $11.02
(-0.10%) $0.798
(0.27%) $93.51
Live Chart Being Loaded With Signals
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 975.00 |
Vidutinė apimtis | 332.00 |
Rinkos kapitalizacija | 68.57B |
EPS | €0 ( 2024-02-12 ) |
Kita pelno data | ( €0 ) 2024-05-22 |
Last Dividend | €0.375 ( 2023-07-20 ) |
Next Dividend | €0 ( N/A ) |
P/E | 31.63 |
ATR14 | €0 (0.00%) |
Zoetis Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Zoetis Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €8.54B |
Bruto pelnas: | €5.98B (70.03 %) |
EPS: | €5.08 |
FY | 2023 |
Pajamos: | €8.54B |
Bruto pelnas: | €5.98B (70.03 %) |
EPS: | €5.08 |
FY | 2022 |
Pajamos: | €8.08B |
Bruto pelnas: | €5.63B (69.63 %) |
EPS: | €4.51 |
FY | 2021 |
Pajamos: | €7.78B |
Bruto pelnas: | €5.47B (70.38 %) |
EPS: | €4.26 |
Financial Reports:
No articles found.
Zoetis Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.325 (N/A) |
€0.325 (N/A) |
€0.375 (N/A) |
€0.375 (N/A) |
€0.375 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.200 | 2020-01-16 |
Last Dividend | €0.375 | 2023-07-20 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | €4.23 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.04 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.75 | |
Div. Directional Score | 7.96 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PBB.DE | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
APC.F | Ex Dividend Knight | 2023-08-11 | Quarterly | 0 | 0.00% | |
HHFA.DE | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
SAP.DE | Ex Dividend Knight | 2023-05-12 | Annually | 0 | 0.00% | |
CBHD.DE | Ex Dividend Knight | 2023-05-15 | Semi-Annually | 0 | 0.00% | |
KHNZ.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
TNE5.DE | Ex Dividend Junior | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
DR0.DE | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
MUB.DE | Ex Dividend Junior | 2023-08-11 | Annually | 0 | 0.00% | |
7BP.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.274 | 1.500 | 4.51 | 6.77 | [0 - 0.5] |
returnOnAssetsTTM | 0.164 | 1.200 | 4.53 | 5.44 | [0 - 0.3] |
returnOnEquityTTM | 0.488 | 1.500 | 5.68 | 8.53 | [0.1 - 1] |
payoutRatioTTM | 0.295 | -1.000 | 7.05 | -7.05 | [0 - 1] |
currentRatioTTM | 3.36 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.770 | 0.800 | 4.30 | 3.44 | [0.8 - 2.5] |
cashRatioTTM | 1.079 | 1.500 | 5.11 | 7.67 | [0.2 - 2] |
debtRatioTTM | 0.473 | -1.500 | 2.12 | -3.18 | [0 - 0.6] |
interestCoverageTTM | 13.61 | 1.000 | 6.07 | 6.07 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.11 | 2.00 | 8.30 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.52 | 2.00 | 8.24 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.352 | -1.500 | 4.59 | -6.89 | [0 - 2.5] |
grossProfitMarginTTM | 0.700 | 1.000 | 1.662 | 1.662 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.381 | 1.000 | 4.39 | 4.39 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.348 | 1.000 | 9.18 | 9.18 | [0.2 - 2] |
assetTurnoverTTM | 0.598 | 0.800 | 9.35 | 7.48 | [0.5 - 2] |
Total Score | 10.17 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 31.42 | 1.000 | 6.93 | 0 | [1 - 100] |
returnOnEquityTTM | 0.488 | 2.50 | 7.23 | 8.53 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.52 | 2.00 | 8.83 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.010 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.11 | 2.00 | 8.30 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.295 | 1.500 | 7.05 | -7.05 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.275 | 1.000 | 5.62 | 0 | [0.1 - 0.5] |
Total Score | 5.75 |
Zoetis Inc
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.